About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

JCR Pharmaceuticals Co.,Ltd.(4552) Summary

4552
TSE Prime
JCR Pharmaceuticals Co.,Ltd.
448
JPY
-19
(-4.07%)
Apr 4, 3:30 pm JST
3.06
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
439.5
Apr 4, 11:43 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.04
Yield
4.46%
Margin Trading Ratio
17.02
Stock Price
Apr 4, 2025
Opening Apr 4, 9:00 am
460 JPY 3.14 USD
Previous Close Apr 3
467 JPY 3.17 USD
High Apr 4, 9:00 am
460 JPY 3.14 USD
Low Apr 4, 1:52 pm
438 JPY 3.01 USD
Volume
990,800
Trading Value
0.45B JPY 3.05M USD
VWAP
449.21 JPY 3.08 USD
Minimum Trading Value
44,800 JPY 306 USD
Market Cap
0.06T JPY 0.40B USD
Number of Trades
1,660
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
Slightly High
1-Year Average
793
1-Year High Mar 28, 2025
3,041
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 46,800 1,305,700 27.90
Mar 21, 2025 15,500 1,321,100 85.23
Mar 14, 2025 14,300 1,312,600 91.79
Mar 7, 2025 15,800 1,358,100 85.96
Feb 28, 2025 12,900 1,317,500 102.13
Company Profile
JCR Pharmaceuticals Co., Ltd. specializes in growth hormone products and focuses on biosimilars. The company collaborates with PeptiDream in creating carrier peptides.
Sector
Pharmaceuticals
JCR Pharmaceuticals Co., Ltd. develops, manufactures, and sells medical pharmaceuticals, regenerative medicine-related products, and pharmaceutical raw materials, primarily targeting rare disease areas. Through its group companies, the company engages in a wide range of activities including purchasing, facility management, market research, clinical trial supervision, pharmaceutical development, and intellectual property management. Internationally, JCR has subsidiaries in Brazil, Europe, and the United States, which handle clinical operations, regulatory affairs, and development tasks. The company also manages the distribution of pharmaceuticals and their raw materials, as well as contract manufacturing. JCR has affiliated companies involved in research and development, manufacturing, and sales in the regenerative medicine field, and has a proven track record in biosimilars.